Pacific Biosciences of California PACB Business Segments — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pacific Biosciences of California in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacific Biosciences of California's business segments — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacific Biosciences of California's business segments — R&D?
- Pacific Biosciences of California (PACB) reported business segments — R&D of $19.61M in Q1 2026.
- How has Pacific Biosciences of California's business segments — R&D changed year-over-year?
- Pacific Biosciences of California's business segments — R&D decreased by 32.5% year-over-year, from $29.05M to $19.61M.
- What is the long-term trend for Pacific Biosciences of California's business segments — R&D?
- Over 3 years (2022 to 2025), Pacific Biosciences of California's business segments — R&D has grown at a -20.4% compound annual growth rate (CAGR), from $193M to $97.31M.
- What does business segments — R&D mean?
- These are the expenditures dedicated to the innovation, design, and improvement of the company's genetic sequencing platforms and software. For a biotechnology firm, this metric is critical for assessing the long-term competitive advantage and the pipeline of future product enhancements.